Bill Will Allow Doctors to Negotiate Jointly With HMOs

Publication
Article
OncologyONCOLOGY Vol 14 No 5
Volume 14
Issue 5

The House Judiciary Committee overwhelmingly approved what has been a controversial bill (H.R. 1304) allowing independent physicians in a given community to negotiate jointly with a managed care plan. Doing so is currently against

The House Judiciary Committee overwhelmingly approved what has been a controversial bill (H.R. 1304) allowing independent physicians in a given community to negotiate jointly with a managed care plan. Doing so is currently against antitrust law. But H.R. 1304, which passed by a vote of 26-2, would provide an exemption that has been sought by nearly every medical provider group, including the AMA, in Washington. Sponsored by Rep. Tom Campbell (R-CA), the bill is opposed by the managed care industry and the Clinton administration, both of which claim that it will enable physicians to greatly increase their fees. “Antitrust exemptions are intended to augment providers’ incomes,” argues Chip Kahn, president of the Health Insurance Association of America (HIAA). But Donald J. Palmisano, MD, an AMA trustee, argues that managed care plans have too much market power over physicians. “The role of physician as patient advocate can be easily undermined when a physician has no leverage in the face of a large, controlling health plan,” states Palmisano. Nearly a majority of House members are cosponsors of H.R. 1304, the House should pass it. Prospects for Senate approval are good, too.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content